Department of Neurosurgery, Faculty of Medicine, Yamagata University, 2-2 Iida-Nishi, Yamagata, Yamagata, 990-9585, Japan.
Department of Radiation Oncology, Faculty of Medicine, Yamagata University, Yamagata, Yamagata, Japan.
Int J Clin Oncol. 2018 Oct;23(5):820-825. doi: 10.1007/s10147-018-1298-z. Epub 2018 May 23.
The optimal treatment for elderly patients with glioblastoma has not been established.
We retrospectively analyzed the safety and efficacy of hypofractionated radiotherapy (45 Gy/15 fr) combined with temozolomide (TMZ) followed by bevacizumab (BEV) salvage treatment in 18 glioblastoma patients aged > 75 years.
All of the patients received safe hypofractionated radiotherapy and concomitant TMZ (75 mg/m), and 14 of 18 patients received maintenance TMZ. We administered BEV to 17 of 18 patients because their Karnofsky Performance Status scores declined and/or recurrence was detected. During the follow-up period (median duration: 17.5 months, range 3-33 months), 12 patients died of their disease. While the median progression-free survival period was 2.5 months, the median overall survival period was 20 months. Adverse events (National Cancer Institute Common Terminology Criteria for Adverse Events grade 3 or 4) occurred in 5 patients.
Hypofractionated radiotherapy combined with TMZ and BEV salvage treatment was found to be safe and effective in glioblastoma patients aged > 75 years.
老年胶质母细胞瘤患者的最佳治疗方法尚未确定。
我们回顾性分析了 18 例年龄>75 岁的胶质母细胞瘤患者接受低分割放疗（45 Gy/15 次）联合替莫唑胺（TMZ）治疗，以及贝伐珠单抗（BEV）挽救治疗的安全性和疗效。
所有患者均接受了安全的低分割放疗和 TMZ （75mg/m2）同步治疗，18 例患者中有 14 例接受了维持 TMZ 治疗。我们对 18 例患者中的 17 例使用了 BEV，因为他们的 Karnofsky 表现状态评分下降和/或发现复发。在随访期间（中位持续时间：17.5 个月，范围 3-33 个月），12 例患者死于疾病。虽然中位无进展生存期为 2.5 个月，但中位总生存期为 20 个月。5 例患者发生不良事件（美国国立癌症研究所不良事件通用术语标准 3 或 4 级）。
低分割放疗联合 TMZ 和 BEV 挽救治疗在年龄>75 岁的胶质母细胞瘤患者中是安全有效的。
